

**Nanopac Innovation Limited**

**ARBN 169 020 580**

**ANNUAL FINANCIAL REPORT**

**FOR THE YEAR ENDED 31 December 2016**

## **CONTENTS**

Corporate Governance Statement

Director's Report

Remuneration Report

Independent Audit Report

Consolidated Statement of Financial Position

Consolidated Statement of Comprehensive Income

Consolidated Statement of Changes in Equity

Consolidated Statement of Cash Flows

Notes to the Financial Statements

Stock Exchange Information

Corporate Directory

## **DIRECTORS GOVERNANCE STATEMENT**

The Board has the responsibility of ensuring that the Company is properly managed so as to protect and enhance shareholders' interests in a manner that is consistent with the Company's responsibility to meet its obligations to governance policies with which it interacts. To this end, the Board has adopted what it believes to be appropriate corporate governance policies and practices having regard to its size and nature of activities.

The main corporate governance policies are summarised below:

### **Director's Access to Independent Advice**

It is the Board's policy that any committees established by the Board should:

- Be entitled to obtain independent professional or other advice at the cost of the Company, unless the Board determines otherwise.
- Be entitled to obtain such resources and information from the Company including direct access to employees of and advisers to the Company as they might require.
- Operate in accordance with the terms of reference established by the Board.

### **Audit Board and Risk**

Board representatives meet with the external auditors at least once a year. The specific activities include assessing and monitoring:

- The adequacy of the Company's internal controls and procedures to ensure compliance with all applicable legal obligations.
- The adequacy of the financial risk management processes.
- The appointment of the external auditor, any reports prepared by the external auditor and listing with the external auditor.

### **Remuneration and Management Succession**

The Board in fulfilling its responsibilities to shareholders by:

- Reviewing and approving the executive remuneration policy to enable the Company to attract and retain executives and Directors who will create value for shareholders;
- Ensuring that the executive remuneration policy demonstrates a clear relationship between key executive performance and remuneration;
- Maintaining a Board that has an appropriate mix of skills and experience to be an effective decision making body; and
- Emerging that the Board is comprised of Directors who contribute to the successful to the successful management of the Company and discharge their duties having regard to the law and the highest standards of corporate governance.

## **DIRECTOR'S REPORT**

Your directors present their report on the Company for the financial period ended 31 December 2016

### **Directors**

The names of directors in office at any time during or since the end of the period are:

Dr. Cheng Kok Leong

Tang Tung Ken

Chin Woi Ho

Dr Cheng has been in office since incorporation on 7 March 2014 until the date of this report.

Mr Tang was in office from incorporation on 7 March 2014 until 30 May 2016.

Mr Chin Woi Ho has been in office since 30 May 2016 until the date of this report

### **Company Secretary**

The position of company secretary from 7 March 2014 has been held by each of Westco Secretaries Ltd and Mr Andrew David Bristow .

### **Principle Activities**

The principal activity of the Company and its subsidiaries is the manufacture distribution and sale of nanotechnology products.

### **Our business model and objectives**

The Company proposes to generate future income by continuing to manufacture distribution and sell nanotechnology products.

It is also the Company's objectives to explore and seek new synergistic partners that could help the Company progress faster and better in terms of new business penetration or new technologies to enhance the profitability of the overall Company's performance financially.

### **Operating Results**

The Company incurred a net operating profit USD109,632 for the period ending 31 December 2016.

#### **Dividends Paid or Recommended**

No dividends have been paid since the date of incorporation and the directors do not recommend the payment of a dividend.

#### **Review of Operations**

During the year the Company entered into agreements for the acquisition of 51% of Segal Lubricant and DNA Petrochem. Construction has yet to commence on a factory for production of nano solar cells as there were some new developments announced by the Malaysian Government to provide special incentives as our project has been recognized as the catalyst project for aiding the government's plan to promote that area into Auto City. The company is focusing on getting the Development Order in place by 2017 so that commencement of construction can begin once the Development Order is obtained.

#### **Financial Position**

The net assets of the Company during the financial period other than those disclosed elsewhere in this report.

#### **Significant Changes in State of Affairs**

There were no significant changes in the state of affairs of the Company during the financial period other than those disclosed elsewhere in this report.

#### **After Balance Date Events**

There have been no events that have affected or may significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in the future since the Balance Date.

#### **Future Developments and Business Strategies**


The Company will pursue its investment objectives for the long-term benefit of members. This will require the continued review of the investment strategy that is in place and may from time to time require some changes to that strategy.

We do not believe it is possible or appropriate to make a prediction on the future course of markets or the performance of our investments. Accordingly, we do not provide a forecast of the likely results of our activities.

#### **Environmental Issues**

The Company's operations are not regulated by any significant environmental regulation under the law of Australia or elsewhere.

Dated 27 March 2017

A handwritten signature in black ink, appearing to be 'J. M. S.', is written over a horizontal line.

**Cheng Kok Leong**  
**Chairman**

**DIRECTORS' REPORT**

**Information on Directors**

**DATA DR CHENG KOK LEONG**

Chairman.

Board member from 7 March 2014 to date.

**Qualification and Experience**

Cheng Kok Leong is the founder of Nanopac Malaysia Sdn Bhd. He is currently the chief executive officer. Mr Cheng is a technopreneur and has more than 18 year's experience in starting up and managing companies. Nanopac established the first Nanotechnology Product manufacturing plant in Malaysia. It was granted Pioneer Company status in 2004 and was recognised as one of Malaysia's fastest growing companies. Mr Cheng was previously CEO and co-founder of DAG Autosonic Sdn Bhd and Digi Sun Technologies Sdn Bhd.

**Interest in Shares and Options**

- 26,250,000 CDIs and 11,200,000 A Class Converting Preference Shares

**Special Responsibilities**

Nil

**Directorships held in other listed Entities**

Nil

**HO CHIN WOI**

Executive Director

Board member from 30 May 2016 to date.

**Qualification and Experience**

Ho Chin Woi obtained his Bachelor of Engineering in Chemical Engineering, and Master of Science majoring in Biochemical Engineering from Universiti Putra Malaysia (UPM), one of the leading research universities in Malaysia. Prior to joining Nanopac in 2009, he was part of a university research team working in the development of large-scale isolation and purification processes for nano-scale virus protein useful for diagnostic reagents and vaccine development. During his 4-year tenure with the research team, he published a total of 5 scientific articles in high ranking scientific journals in South Korea and United Kingdom. His research effort has earned him numerous international awards including the gold medals in the 17th Malaysia International Invention & Technology Exhibition (ITEX 2006) and in the 55th World Exhibition on Innovation, Research and New Technologies, Brussels, Belgium (EUREKA 2006).

He originally joined Nanopac (M) Sdn Bhd as an executive in business development. 3 years later, he was promoted to the position of manager in the business development and technical department. He is also currently the Chief Operating Officer of Nanotextile Sdn Bhd, a joint-venture company between Nanopac and NanoMalaysia Berhad, a government agency under the Malaysian Ministry of Science, Technology and Innovation (MOSTI).

Interest in Shares and Options

5,536 CDIs

Special Responsibilities

Nil

Directorships held in other listed Entities

Nil



**Nanopac Innovation Limited**

**ARBN 169 020 580**

---

**REMUNERATION REPORT (Unaudited)**

This report details the nature and amount of remuneration for each director of Nanopac Innovation Limited, and for the executives receiving the highest remuneration.

**Remuneration Policy**

All issues in relation of both Executive Directors and Non-Executive Directors are dealt with by the Board as a whole.

The Constitution of Nanopac Innovation Limited requires approval by the shareholders in general meetings of a maximum amount for consideration in general meeting, and in determining the allocation, the Board takes account of the time demands made on Directors, together with such factors as the general level of fees paid to Directors. The amount of remuneration currently approved by shareholders for Non-Executive Directors is a maximum of \$50,000 per annum.

Non-Executive Directors hold office until such as they retire, resign or are removed from office under the terms set out in the constitution of the Company. Non-Executive Directors do not receive any performance based remuneration.

**Details of remuneration for period ended 31 December 2016**

Details of the remuneration for each Director of the Company was as follows:

Name	Salary & Fees	Super-annuation Contributions	Other	Total
	\$	\$	\$	\$
Cheng Kok Leong	91,202.80	Nil	Nil	91,202.80
Ton Tung Ken	20,332.16	Nil	Nil	20,332.16
Ho Chin Woi	28,465.04	Nil	Nil	28,465.04

# **CK & ASSOCIATES** (AF 1598)

Chartered Accountants

(Member Firm of the Malaysian Institute of Accountants)

---

Unit A-6-2, Wisma Yoon Cheng, No. 726, Batu 4½,  
Jalan Ipoh, 51200 Kuala Lumpur.

Tel : 03-6257 1423 , 03-6257 9902

Fax : 03-6257 0523

Email : associatesck@gmail.com

## **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NANOPAC INNOVATIONS LIMITED**

### **Report on the Audit of the Financial Statements**

#### **Opinion**

We have audited the financial statements of NANOPAC INNOVATIONS LIMITED., which comprise the statements of financial position of the Group as at 31 December 2016 and the statements of comprehensive income, statements of changes in equity and statements of cash flows of the Group for the year then ended and a summary of significant accounting policies and other explanatory information, as set out on pages 1 to 17.

In our opinion, the accompanying financial statements have been properly drawn up in accordance with International Accounting and Financial Reporting Standards and the requirement of Companies Act, 2016 in Malaysia so as to give a true and fair view of the financial position of the Group as at 31 December 2016 and of its financial performance and cash flows for the year then ended.

#### **Basis for Opinion**

We conducted our audit in accordance with approved standards on auditing in Malaysia and International Standards on Auditing. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Independence and Other Ethical Responsibilities**

We are independent of the Company in accordance with the Bye-Laws (on Professional Ethics, Conduct and Practice) of the Malaysian Institute of Accountants ("By-Laws") and the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants ("IESBA Code") and we have fulfilled our other ethical responsibilities in accordance with the Bye-Laws and the IESBA Code.

#### **Information Other Than The Financial Statements and Auditors' Report Thereon**

The directors of the Company are responsible for the other information. The other information comprises the Directors' Report but does not include the financial statements of the Company and our auditors' report thereon.

## **CK & ASSOCIATES** (AF 1598)

Chartered Accountants

(Member Firm of the Malaysian Institute of Accountants)

---

Unit A-6-2, Wisma Yoon Cheng, No. 726, Batu 4½,  
Jalan Ipoh, 51200 Kuala Lumpur.

Tel : 03-6257 1423 , 03-6257 9902

Fax : 03-6257 0523

Email : associatesck@gmail.com

### **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF**

#### **NANOPAC INNOVATIONS LIMITED**

(Continued)

#### **Information Other than the Financial Statements and Auditors' Report Thereon (Continued)**

Our opinion on the financial statements of the Company does not cover the Directors' Report and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements of the Company, our responsibility is to read the Directors' Report and, in doing so, consider whether the Directors' Report is materially inconsistent with the financial statements of the Company or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of the Directors' Report, we are required to report that fact. We have nothing to report in this regard.

#### **Responsibilities of the Directors for the Financial Statements**

The directors of the Company are responsible for the preparation of financial statements that give true and fair view in accordance with International Accounting and Financial Reporting Standards and the requirement of Companies Act, 2016 in Malaysia. The directors are also responsible for such internal control as the directors determine is necessary to enable the preparation of financial statements of the Company that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements of the Company, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

#### **Auditors' Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements of the Company as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with approved standards on auditing in Malaysia and International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

## **CK & ASSOCIATES** (AF 1598)

Chartered Accountants

(Member Firm of the Malaysian Institute of Accountants)

Unit A-6-2, Wisma Yoon Cheng, No. 726, Batu 4½,  
Jalan Ipoh, 51200 Kuala Lumpur.

Tel : 03-6257 1423 , 03-6257 9902

Fax : 03-6257 0523

Email : associatesck@gmail.com

### **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NANOPAC INNOVATIONS LIMITED**

(Continued)

#### **Auditors' Responsibilities for the Audit of the Financial Statements (Continued)**

As part of an audit in accordance with approved standards on auditing in Malaysia, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:-

- Identify and assess the risks of material misstatement of the financial statements of the Company, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements of the Company or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements of the Company, including the disclosures, and whether the financial statements of the Company represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

## **CK & ASSOCIATES** (AF 1598)

Chartered Accountants  
(Member Firm of the Malaysian Institute of Accountants)

Unit A-6-2, Wisma Yoon Cheng, No. 726, Batu 4½,  
Jalan Ipoh, 51200 Kuala Lumpur.

Tel : 03-6257 1423 , 03-6257 9902

Fax : 03-6257 0523

Email : associatesck@gmail.com

### **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NANOPAC INNOVATIONS LIMITED**

(Continued)

#### **Auditors' Responsibilities for the Audit of the Financial Statements (Continued)**

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial statements of the Company for the current year and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### **Report on Other Legal and Regulatory Requirements**

In accordance with the requirements of the Companies Act 2016 in Malaysia, we also report the following:-

- a) In our opinion, the accounting and other records and the registers required to be kept by the Company and its subsidiaries of which we have acted as auditors have been properly kept in accordance with the provisions of the Act.
- b) We have considered the accounts and auditors' report of all the subsidiaries of which we have not acted as auditors being accounts that have been included in the consolidated financial statements.
- c) We are satisfied that the accounts of the subsidiaries that have been consolidated with the Company's financial statements are in form and content appropriate and proper for the purposes of the preparation of the financial statements of the Group and we have received satisfactory information and explanations as required by us for those purposes.
- d) The audit reports on the accounts of the subsidiaries did not contain any qualification or any adverse comment made under Section 266 (2) of the Act.

**CK & ASSOCIATES** (AF 1598)

Chartered Accountants

(Member Firm of the Malaysian Institute of Accountants)

Unit A-6-2, Wisma Yoon Cheng, No. 726, Batu 4½,  
Jalan Ipoh, 51200 Kuala Lumpur.

Tel : 03-6257 1423 , 03-6257 9902

Fax : 03-6257 0523

Email : associatesck@gmail.com

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF  
NANOPAC INNOVATIONS LIMITED**

(Continued)

**Other Matters**

This report is made solely to the members of the Company, as a body, in accordance with Section 266 of the Companies Act, 2016 in Malaysia and for no other purpose. We do not assume responsibility to any other person for the content of this report.



**CK & ASSOCIATES**  
**AF: 1598**  
**Chartered Accountants**

Kuala Lumpur

Date: 30 March 2017



**CHONG CHOONG KONG**  
**No: 02226/01/2018 J**  
**Chartered Accountant**

NANOPAC INNOVATION LIMITED

CONSOLIDATED STATEMENT OF PROFIT OR LOSS FOR THE YEAR ENDED 31 DECEMBER 2016

	2016 USD	2015 USD
Revenue	2,313,814	4,502,685
Cost of sales	(1,341,122)	(3,820,383)
<b>Gross profit</b>	<b>972,691</b>	<b>682,302</b>
Administrative expenses	(331,896)	(402,932)
Selling and marketing expenses	(498,002)	(11,373)
Other operating expenses	(20,026)	(163,502)
	(849,924)	(577,806)
<b>Operating profit</b>	<b>122,767</b>	<b>104,496</b>
Other operating income	1,958	6
Finance costs	(163)	(975)
<b>Profit before tax</b>	<b>124,561</b>	<b>103,527</b>
Taxation	(14,929)	-
<b>PROFIT AFTER TAX</b>	<b>109,632</b>	<b>103,527</b>
Exchange Gain/(Loss) on translating foreign operations	-	-
	<b>109,632</b>	<b>103,527</b>
<b>Earnings per share basic and diluted - attributable to the Shareholder of parent company</b>	<b>0.0016</b>	<b>0.0020</b>

The annexed notes from 1 to 24 form an integral part of these financial statements.

  
 DIRECTOR  
 CHENG KOK LEONG

  
 DIRECTOR  
 HO CHIN WOI



NANOPAC INNOVATION LIMITED  
CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 31 DECEMBER 2016

	Note	2016 USD	2015 USD
Profit for the year		109,632	103,527
<i>Other comprehensive income</i>			
<i>Items that may not be reclassified subsequently to profit or loss account:</i>			
Exchange Gain/(Loss) on translating foreign operations		6,700	2,219
Income tax relating to items that may be reclassified	17	-	-
		<u>6,700</u>	<u>2,219</u>
		<u>116,332</u>	<u>105,746</u>

The annexed notes from 1 to 24 form an integral part of these financial statements.

  
\_\_\_\_\_  
DIRECTOR  
CHENG KOK LEONG

  
\_\_\_\_\_  
DIRECTOR  
HO CHIN WOI








**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE INCOME**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

	Share capital		Reserves			Total equity and reserves
	Ordinary	Convertible	Foreign currency translation reserve	Consolidated retained earnings	Total reserves	
	USD					
Shares issued during the period	500,000	2,750,993	-	-	-	3,250,993
Profit for the period ended 31 December 2015	-	-	-	3,131,541	3,131,541	3,131,541
Other comprehensive income	-	-	63,933	-	63,933	63,933
<b>Balance as at 31 December 2015</b>	<b>500,000</b>	<b>2,750,993</b>	<b>63,933</b>	<b>3,131,541</b>	<b>3,195,474</b>	<b>6,446,467</b>
Shares issued during the period	-	4,630,698	-	-	-	4,630,698
Profit for the period ended 31 December 2016	-	-	-	109,632	109,632	109,632
Other comprehensive income	-	-	6,700	-	6,700	6,700
<b>Balance as at 31 December 2016</b>	<b>500,000</b>	<b>7,381,691</b>	<b>70,633</b>	<b>3,241,173</b>	<b>3,311,806</b>	<b>11,193,497</b>

The annexed notes from 1 to 24 form an integral part of these financial statements.

  
 DIRECTOR  
**CHENG KOK LEONG**



  
 DIRECTOR  
**HO CHIN WOI**

**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2016**

	2016 USD	2015 USD
<b>ASSETS</b>		
<b>NON CURRENT ASSETS</b>		
Property, plant and equipment	3,749,888	2,483,032
Intangible assets	4,634	6,234
Investment in subsidiaries	98,909	-
	<b>3,853,431</b>	<b>2,489,266</b>
<b>CURRENT ASSETS</b>		
Stock in trade	190,977	79,683
Trade receivables	5,194,508	4,238,207
Deposits and other receivables	2,098,124	62,536
Cash and bank balances	1,122,242	909,988
	<b>8,605,852</b>	<b>5,290,414</b>
<b>TOTAL ASSETS</b>	<b>12,459,283</b>	<b>7,779,680</b>
<b>EQUITY AND LIABILITIES</b>		
<b>SHARE CAPITAL AND RESERVES</b>		
Authorized share capital	14,000,001	14,000,001
Issued, subscribed and paid up capital	7,881,691	3,250,993
Consolidated retained earnings	3,311,806	3,195,474
<b>Shareholder's equity</b>	<b>11,193,497</b>	<b>6,446,467</b>
<b>CURRENT LIABILITIES</b>		
Trade payables	255,224	80,423
Term loan	138,879	388,873
Due to subsidiary	66,875	86,363
HP creditors	448,100	-
Accruals and deposits received	-	682,844
Amount due to a director	356,707	94,710
	<b>1,265,785</b>	<b>1,333,213</b>
<b>CONTINGENCIES AND COMMITMENTS</b>		
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>12,459,283</b>	<b>7,779,680</b>

The annexed notes from 1 to 24 form an integral part of these financial statements.

  
DIRECTOR  
**CHENG KOK LEONG**

  
DIRECTOR  
**HO CHIN WOI**



**NANOPAC INNOVATION LIMITED**

**CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2016**

	2016 USD	2015 USD
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit before taxation	109,632	103,527
Adjustments for:		
- Exchange difference on translation of foreign operations	6,700	2,219
- Financial charges	163	975
- Depreciation	153,252	282,668
- Amortization	1,246	1,600
	<u>161,361</u>	<u>287,462</u>
<b>Operating profit before working capital changes</b>	<b>270,993</b>	<b>390,989</b>
<b>WORKING CAPITAL CHANGES</b>		
<b>(Increase)/(decrease) in current assets</b>		
Stock in trade	(111,294)	(67,368)
Trade receivables	(956,300)	(2,286,104)
Deposits and other receivables	(2,035,588)	(61,105)
Tax refund due from government	-	-
<b>(Increase)/(decrease) in current liabilities</b>		
Trade payables	174,801	(35,404)
Term loan	(249,994)	388,873
Due to subsidiary	(19,488)	86,362
HP creditors	448,100	(36,040)
Accruals and deposits received	(682,844)	132,489
Amount due to directors	261,996	65,456
	<u>(3,170,611)</u>	<u>(1,812,841)</u>
<b>Cash generated from operations</b>	<b>(2,899,618)</b>	<b>(1,421,852)</b>
- Finance cost paid	(163)	(975)
<b>Net cash inflows from operating activities</b>	<b>(2,899,781)</b>	<b>(1,422,827)</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
Cash of subsidiary on acquisition date	-	-
Fixed Assets purchased	(1,419,754)	(1,352,360)
Investment in subsidiaries	(98,909)	-
Intangibles purchased	-	-
<b>Net cash inflows from investing activities</b>	<b>(1,518,663)</b>	<b>(1,352,360)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Shares issued during the period	4,630,698	2,550,993
<b>Net cash inflows/(outflows) from financing activities</b>	<b>4,630,698</b>	<b>2,550,993</b>
<b>Net increase in cash and cash equivalents</b>	<b>212,254</b>	<b>(224,194)</b>
Cash and cash equivalents at beginning of the period	909,988	1,134,182
<b>Cash and cash equivalents at the end of the period</b>	<b>1,122,242</b>	<b>909,988</b>

The annexed notes from 1 to 24 form an integral part of these financial statements.

  
 DIRECTOR  
 CHENG KOK LEONG

  
 DIRECTOR  
 HO CHIN WOI

**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

---

**1. STATUS AND NATURE OF BUSINESS**

The Group consist of the following companies:

**1.1 Holding company**

Nanopac Innovation Ltd was incorporated under the International Companies Act, 1987 in Samoa as an international company on the March 07, 2014. The registered office of the company is situated at Level 2, Lotemau Centre, Vaea Street, Apia, Samoa. The principal activities of the company are investment holding and engaged in manufacturing, supplying, importing, exporting of nano technology products, photo catalyst power, coating solutions and chemical solutions of every description.

**1.2 Subsidiary company**

Nanopac (M) Sdn. Bhd. (634805-K) is a private limited liability company incorporated and domiciled in Malaysia. The principal activities of the company are investment holding and engaged in manufacturing, supplying, importing, exporting of nano technology products, photo catalyst power, coating solutions and chemical solutions of every description. There have been no significant changes in the nature of these activities during the financial year. The registered office of the company is at 67-1, Jalan Puteri 5/7, Bandar Puteri, 47100 Puchong, Selangor Darul Ehsan. The address of the principal place of business of the company is No 27, Jalan Rajawali 2, Bandar Puchong Jaya, 47100 Puchong, Selangor Darul Ehsan. Segal Lubricant Sdn. Bhd. (985702-U) and DNA Petrochem Sdn Bhd (941525-D) are private limited liability company incorporated and domiciled in Malaysia. The principal activities of the company are investment holding and engaged in manufacturing, supplying, importing and exporting of engine oil products. There are the subsidiary companies of Nanopac (M) Sdn Bhd.

**2. BASIS OF PREPARATION**

**2.1 Basis of measurement**

The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and have been prepared on a historical cost basis.

**2.2 Basis of consolidation**

The consolidated financial statements incorporate the financial statements of the company and its subsidiary made up to 31 December 2016 using uniting of interest method.

Under the uniting of interest method, the cost of the business combination is measured at the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred or assumed, and equity. At the acquisition date, the cost of the business combination is allocated to identifiable assets, liabilities and contingent liabilities in the business combination which are measured initially at closing values at the acquisition date. The excess of the cost of business combination over the Group's interest in the net closing value of the identifiable assets, liabilities and contingent liabilities, the Group will:

a) Reassess the identification and assessment of the acquiree's identifiable assets, liabilities and contingent liabilities and measurement of the cost of the combination; and

b) Recognise immediately in profit and loss any excess remaining after that assessment.

Subsidiaries are consolidated from the acquisition date, which is the date on which the group effectively obtains control, until the date on which the group ceases to control the subsidiaries. Control exists when the group has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. In assessing control, potential voting rights that are exercisable are taken into account.

**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

---

Intragroup balances, transactions and unrealized gains and losses on the intragroup transactions are eliminated in full. Intragroup losses may indicate an impairment that requires recognition in consolidated financial statements. If a subsidiary uses accounting policies other than those adopted in the consolidated financial statements for transactions or events in similar circumstances, appropriate adjustments are made to its financial statements in preparing consolidated financial statements.

The gain or loss on the disposal of a subsidiary, which the difference between the net disposal proceeds and the Group's share of its net assets as of the date of disposal including the carrying amount of goodwill and the cumulative amount of any exchange differences that relate to the subsidiary, recognized in the consolidated statement of comprehensive income.

Under the uniting of interest method, the cost of business combination is measured at the aggregate of fair values at the date of exchange, of assets given, liabilities incurred or assumed, and equity instruments issued. Non controlling interest is that portion of the profit or loss and net assets of the subsidiary attributable to the equity interests that are not owned, directly and indirectly through subsidiaries, by the group. It is measured at the non controlling interest share of the fair value of the subsidiaries identifiable assets and liabilities at the acquisition date and the non controlling interest share of changes in the subsidiaries equity since that date.

**2.3 Statement of compliance**

These financial statements have been prepared in accordance with the International Accounting and Financial Reporting Standards and the requirements of the Samoa's International Companies Act, 1987. In case requirements differ, the provisions or directives of the International Companies Act, 1987 shall prevail.

**3. STANDARDS, INTERPRETATIONS AND AMENDMENTS TO PUBLISHED APPROVED ACCOUNTING STANDARDS**

**3.1 Standards, amendments and interpretations which became effective during the year**

Below is the list of the amendments to IFRSs and the new interpretations that are mandatorily effective for accounting periods that begin on or after 1 January 2015.

- Amendments to IFRS 10 and IAS 27 Investment Entities; and
- Amendments to IAS 39 Novation of Derivatives and Continuation of Hedge Accounting.

**Amendments to IFRS 10 and IAS 27 Investment Entities**

The amendments to IFRS 10 define an investment entity and introduce an exception from the requirement to consolidate subsidiaries for an investment entity. In terms of the exception, an investment entity is required to measure its interests in subsidiaries at fair value through profit or loss. The exception does not apply to subsidiaries of investment entities that provide services that relate to the investment entity's investment activities.

To qualify as an investment entity, certain criteria have to be met. Specifically, an entity is an investment entity when it:

- obtains funds from one or more investors for the purpose of providing them with investment management services;
- commits to its investor(s) that its business purpose is to invest funds solely for returns from capital appreciation, investment income, or both; and
- measures and evaluates performance of substantially all of its investments on a fair value basis.

**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

---

Consequential amendments to IFRS 12 and IAS 27 have been made to introduce new disclosure requirements for investment entities. In general, the amendments require retrospective application, with specific transitional provisions.

**Amendments to AIS 39 Continuation of Hedge Accounting**

The amendments to IAS 39 permits an entity to apply the hedge accounting requirements, for a fair value hedge of the interest rate exposure of a portion of a portfolio of financial assets and liabilities when IFRS 9 is applied, and to extend the fair value option to certain contracts that meet the "own

**3.2 Standards, amendments and interpretations issued but not yet effective**

Below is a list of new and revised IFRSs that are not yet mandatorily effective (but allow early application) for the year ending 31 December 2016:

- IFRS 5 Discontinued operations; Annual improvements
- IFRS 7 Financial instruments; Annual improvements
- IFRS 9 Financial instruments;
- IFRS 14 Regulatory Deferral Accounts;
- IFRS 15 Revenue from Contracts with Customers;
- IFRS 16 Leases
- Amendments to IFRS 11 Accounting for Acquisitions of interests in Joint Operations
- IAS 01-Presentation of Financial Statements - Disclosure Initiative (Amendment)
- IAS 16 - Property, Plant and Equipment and IAS - 38 Intangible Assets - Clarification of Acceptable Method of Depreciation and Amortization (Amendment).
- IAS 19 Employees Benefit; Annual Improvements
- IAS 27 - Separate Financial Statements - Equity Method in Separate Financial Statements (Amendment)
- Amendments to IAS 28 Investment in associates and joint ventures; Sale or Contribution of assets, Consolidation exceptions.

There are a number of other minor amendments and interpretations to other approved accounting standards that are not yet effective and are also not relevant to the Company and therefore have not been presented here.

**4 SIGNIFICANT ACCOUNTING, JUDGEMENTS, ESTIMATES AND ASSUMPTIONS**

The preparation of the company's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The company based its assumptions and estimates on parameters available when the financial statements were prepared. Exiting circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the company.

**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

---

**4.1 Measurement of fair value**

When measuring the fair value of assets and liabilities, the company uses market observables data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as stated in Note 17 to these financial statements.

**4.2 Revenue Recognition**

In making their judgement, the directors considered the detailed criteria for the recognition of revenue from the rendering of services as set out in IAS 18 and, in particular, whether the company has established the right to record the said revenue.

**5 SIGNIFICANT OF ACCOUNTING POLICIES**

**5.1 Functional and presentation currency**

These financial statements are prepared in US Dollars, which is the company's functional as well as presentation currency.

**5.2 Foreign currency**

Transactions in foreign currencies during the financial year are converted into United States Dollars (USD) at exchange rates ruling at the transaction dates. Foreign currency monetary assets and liabilities at the statement of financial position date are transacted into USD at exchange rates ruling at that date. All exchange gains or losses are dealt with in the income statement.

**5.3 Trade and other receivables**

Receivables are stated at anticipated realizable value. Bad debts are written off in the period in which they are identified. Allowance for bad and doubtful debts is made on estimates of possible losses which may arise from non-collection of certain debts.

**5.4 Financial instruments**

Financial instruments are recognized in the Statement of financial position when the Company is a party to the contractual provision of the instruments. The recognized financial instruments of the company in the statement of financial position comprise cash and cash equivalents, investments, short term loans and interest receivables that arise directly from its operations, non-trade receivables and payables arising from transactions entered into in the normal course of business, borrowings, and ordinary share capital. The company classifies its financial assets into following measurement categories.

- Financial assets at fair value through profit or loss
- Loans and receivables
- Held to maturity
- Available for sale

Financial liabilities are classified as either held at fair value through profit or loss or at amortized cost. Management determines the classification of financial assets and liabilities at initial recognition or, where appropriate, at the time of reclassification.

**5.5 Cash and cash equivalent**

Cash and cash equivalents consist of cash in hand, balances and deposits with banks and highly liquid investments which have a significant risk of changes in value. For the purpose of the cash flow statement, cash and cash equivalents are presented.

**5.6 Trade creditors**

Payables are stated at their nominal values which are the fair values of the consideration to be paid in the future for goods and services rendered.

**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

---

**5.7 Revenue recognition**

Revenue comprises the fair value of the consideration received or receivable for the rendering of services in the ordinary course of the company's business, revenue is recognized when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the company and specific criteria has been met for each of the company's activities as described below:

**Rendering of services**

Revenue from contracts is recognized on accrual basis

The recognition of revenue to the stage of completion of a transaction is often referred to as the percentage of completion method. Under this method, revenue is recognized in the accounting periods in which the services are rendered. The recognition of revenue on this basis provides useful information on the extent of service activity and performance during a period.

**Interest / Mark up income**

Interest / Mark up is recognized on a time proportion basis by reference to the principal outstanding and the applicable rate of return.

**5.8 Offsetting**

Financial assets and liabilities are offset and the net amount is reported in the statement of financial position, if the company has a legally enforceable right to offset the recognized amounts and the company intends to settle either on a net basis or realize the asset and settle the liability.



**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

**6 PROPERTY, PLANT AND EQUIPMENT**

Particulars	COST			Rate %	DEPRECIATION			WDV as on 31 Dec 2016
	As on 1 Jan 2016	Addition during the year	As on 31 Dec 2016		As on 1 Jan 2016	For the Period	As on 31 Dec 2016	
USD							USD	
Land and building	1,352,360	998,493	2,350,853	-	-	-	-	2,350,853
Motor vehicles	-	233,421	233,421	20	-	46,684	46,684	186,737
Office equipment	8,856	122,965	131,821	20	6,477	26,364	32,841	98,979
Computer	10,545	4,262	14,807	20	8,977	2,961	11,938	2,869
Machinery	4,238,202	244,602	4,482,804	10	3,113,044	356,051	3,469,095	1,013,709
Renovation	5,176	120,262	125,438	20	3,609	25,088	28,697	96,741
Total	5,615,139	1,724,005	7,339,144		3,132,107	457,148	3,589,255	3,749,888

**7 INTANGIBLE ASSETS**

Particulars	COST			Rate %	DEPRECIATION			WDV as on 31 Dec 2016
	As on 1 Jan 2016	Addition during the year	As on 31 Dec 2016		As on 1 Jan 2016	For the Period	As on 31 Dec 2016	
USD							USD	
Software	8,000	-	8,000	20	1,766	1,600	3,366	4,634
Total	8,000	-	8,000		1,766	1,600	3,366	4,634

**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

	2016 USD	2015 USD
<b>8. STOCK IN TRADE</b>		
- Nano technology products	<u>190,977</u>	<u>79,683</u>
<b>9. TRADE RECEIVABLES</b>		
The Company's normal trade credit terms vary from 30 to 90 days. Other trade credit terms are assessed and approved on a case-by-case basis.		
	2016 USD	2015 USD
<b>10. DEPOSITS AND OTHER RECEIVABLES</b>		
Other receivables	2,098,124	60,474
Deposits	-	2,062
	<u>2,098,124</u>	<u>62,536</u>
	2016 USD	2015 USD
<b>11. CASH AND BANK BALANCE</b>		
Cash in hand	-	-
Cash at bank:		
- current accounts	-	-
- saving accounts	1,122,242	909,988
	<u>1,122,242</u>	<u>909,988</u>
	2016 USD	2015 USD
<b>12. SHARE CAPITAL</b>		
<b>Authorized share capital</b>		
<b>Ordinary Share Capital</b>		
1,000,000,000 ordinary shares of USD 0.01 each	10,000,000	10,000,000
1 founder share of USD 1.00 each	1	1
	10,000,001	10,000,001
<b>Convertible Shares</b>		
400,000,000 convertible shares of USD 0.01 each	4,000,000	4,000,000
	<u>14,000,001</u>	<u>14,000,001</u>
<b>12. Issued, subscribed and paid up share capital</b>		
<b>Ordinary Share Capital</b>		
500,000,000 shares of USD 0.01 each	500,000	500,000
<b>Convertible Share Capital</b>		
20,000,000 shares of USD 0.01 each	3,250,993	200,000
	4,630,698	2,550,993
	<u>7,881,691</u>	<u>3,250,993</u>

Note

- 12.1** The convertible shares are convertible at the option of the company once the company has raised additional capital in excess of USD 30 million. These shares are not entitled to the dividends declared by the company before any conversion. The company retained the right to either convert the shares into ordinary shares or to pay them off and redeem them.

**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

**13. CONSOLIDATED RETAINED EARNINGS**

Under the single-tier tax system which came into effect from the year of assessment 2008, companies are not required to have tax credits under Section 108 of the Malaysian income Tax Act 1967 for dividend purposes. Dividends paid under this system are tax exempt in the hands of shareholders.

**14. TRADE PAYABLES**

The normal trade credit terms granted to the company vary from 30 to 60 days.

**15. CONTINGENCIES AND COMMITMENTS**

**CONTINGENCIES:**

There were no contingencies as on the statement of financial position date.

**COMMITMENTS:**

There were no capital commitments as on the statement of financial position date.

**16. REVENUE**

Revenue represents invoiced value from sales of nanotechnology products less return inwards and discount allowed.

**17. TAXATION**

According to the management of the group, the parent company as well as its subsidiary company are not liable to pay any tax in any jurisdiction.

**18. EARNINGS PER SHARES**

		2016	2015
		USD	USD
Profit after taxation for the year	USD	109,632	103,527
Weighted average number of ordinary	Number of shares	70,000,000	55,037,279
Earnings per share - basic and diluted	USD	<u>0.0016</u>	<u>0.0019</u>

**18.1** There is no dilutive effect on basic earnings per share.

**19. BUSINESS COMBINATION**

As at July 16, 2014 the company acquired Nanopac Innovation Ltd., a company with its registered office in Hong Kong.

The acquisition was accounted for by applying the purchase method. The cost of the acquisition was measured at the fair value of the consideration given. Identified assets acquired, liabilities assumed or incurred have been carried at the fair value as at the acquisition date.

	2014
	USD
Fair value of identifiable net assets at date of acquisition	3,338,848
Percentage of identifiable net assets acquired	100%
Purchase consideration paid in ordinary shares of the company	575,000
<b>Bargain Purchase Gain</b>	<u><u>2,763,848</u></u>

**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

	2016	2015
	USD	USD
<b>20. FINANCIAL INSTRUMENTS</b>		
<b>20.1 Financial instruments by class and category</b>		
Financial assets		
Stock in trade	190,977	79,683
Trade receivables	5,194,508	4,238,207
Deposits and other receivables	2,098,124	62,536
Cash and bank balance	1,122,242	909,988
	<u>8,605,852</u>	<u>5,290,414</u>

**20.2 Fair values of financial instruments**

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction in the principal market at the measurement date under current market conditions regardless of whether that price is directly observable or estimated using another valuation technique. As at the reporting date, fair values of all financial instruments are considered to approximate their carrying amounts. Further, there are no fair value estimation uncertainties.

**20.2.1 Methods of determining fair values**

Fair values of financial instruments for which prices are available from the active market are measured by reference to those market prices. The fair value of financial assets (other than investments) and liabilities with no active market are determined in accordance with generally accepted pricing models based on discounted cash flow analysis based on inputs from other than observable market.

**20.2.2 Discount/interest rates used for determining fair values**

The interest rates used to discount estimated cash flows, when applicable, are based on the government yield curve as at the reporting date plus an adequate credit spread.

**20.2.3 Fair value hierarchy**

The Company classifies fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

**Level 1** Quoted prices (unadjusted) in active markets for identical assets or liabilities.

**Level 2** Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from market).

**Level 3** Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs)

The fair value hierarchy of financial assets measured at fair value is as follows:

	2016			
	Total	Level 1	Level 2	Level 3
Stock in trade	115,020	-	-	115,020
Trade receivables	6,154,559	-	-	6,154,559
Deposits and other receivables	57,856	-	-	57,856
Cash and bank balance	1,132,913	-	-	1,132,913
	<u>7,460,349</u>	<u>-</u>	<u>-</u>	<u>7,460,349</u>

**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

	2015			
	Total	Level 1	Level 2	Level 3
Stock in trade	79,683	-	-	79,683
Trade receivables	4,238,207	-	-	4,238,207
Deposits and other receivables	62,536	-	-	62,536
Cash and bank balance	909,988	-	-	909,988
	<u>5,290,414</u>	<u>-</u>	<u>-</u>	<u>5,290,414</u>

## **21 FINANCIAL RISK MANAGEMENT**

### **Financial risk factors**

Financial instruments comprise investment in equity instruments, interest accrued, trade debts, cash and bank balances, short term borrowings and trade and other payables, short term investments.

The company has exposure to the following risks from its use of financial instruments:

#### **Market risk**

#### **Liquidity risk**

#### **Credit risk**

The Board of Directors has the overall responsibility for the establishment and oversight of company's risk management framework. The Board is also responsible for developing and monitoring the company's risk management policies.

The company's risk management policies are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed and regularly to react to changes in market conditions and the company's activities.

The note presents information about the company's exposure to each of the above risks, the company's objectives, policies and processes for measuring and managing risk, and the company's management of capital.

### **21.1 Market risk**

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return.

#### **Currency risk**

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. Currency risk arises mainly from future commercial transactions or receivables and payables that exist.

The company's exposure to currency risk arising from currency exposure to the United States Dollar (USD) on amounts placed with scheduled banks in foreign currency account.

#### **Interest rate risk**

This represents the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

The company has no significant interest-bearing assets.

#### **Interest rate risk management**

The company manages interest rate risk by analyzing its interest rate exposure on dynamic basis. Cash flow interest rate risk is managed by simulating various scenarios taking into consideration refinancing, renewal of existing positions and alternative financing. Based on these scenarios the company calculates impact on profit after taxation and equity of defined interest rate shift, mostly 100 basis points.

**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

**21.2 Credit risk**

Credit risk represents the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge on obligation. The carrying amount of financial assets represents the maximum credit exposure. The credit quality of financial assets that are neither past due nor impaired can be assessed by reference to external credit ratings (if available) or to historical information about counterparty default rate.

The maximum exposure to credit risk at the reporting date was as follows:

	2016	2015
	USD	USD
<b>21.2.1 Maximum exposure to credit risk</b>		
The maximum exposure to credit risk as at the reporting date is as follows:		
Stock in trade	190,977	79,683
Trade receivables	5,194,508	4,238,207
Deposits and other receivables	2,098,124	62,536
Cash and bank balance	1,122,242	909,988
	<u>8,605,852</u>	<u>5,290,414</u>

**21.2.2 Concentration of credit risk**

Concentration of credit risk exists when changes in economic or industry factors similarly affect groups of counterparties whose aggregate credit exposure is significant in relation to the Company's total credit exposure. The Company's portfolio of financial instruments is classified in its funds managed by it and transactions are entered into with diverse credit-worthy counterparties thereby mitigating any significant concentration of credit risk.

**21.2.3 Credit quality and impairment**

Credit quality of financial assets is assessed by reference to external ratings, where available, or to historical information about counterparty default rates.

**21.2.3.1 Counterparties with external credit ratings**

These include banking companies, which are counter parties to bank balances, various aother organizations which are counter parties to investments in debt securities and dividend and profit recivable thereon. These counterparties have reasonably high ratings based on which non-performance by these counterparties is not expected.

**21.2.3.2 Counterparties without external credit ratings**

These include trade receivables and receivable from shareholders. Non performance by these counterparties is not expected.

**21.2.4 Collateral held**

The Company does not hold any collateral to secure its financial assets.

**21.2.5 Credit risk management**

The Company's credit risk is primarily attributable to its investment in its funds, balances with banks, and security deposits. Bank balances are maintained with counter parties that are banking companies with reasonably high credit ratings. The risk of default is considered minimal in case of investments in debt

**21.3 Liquidity risk**

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial laibilities.

**NANOPAC INNOVATION LIMITED**  
**CONSOLIDATED NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2016**

---

The company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses.

**22. RELATED PARTY TRANSACTIONS**

Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. There are no related party transactions in the year.

**23. DATE OF AUTHORIZATION FOR ISSUE**

These financial statements have been approved and authorized for issue on \_\_\_\_\_ by the Board of Directors of the parent company.

**24. GENERAL**

- Figures have been rounded off to the nearest US Dollar.
- Corresponding figures have been rearranged or reclassified, whenever necessary for the purpose of comparison.



DIRECTOR  
CHENG KOK LEONG



DIRECTOR  
HO CHIN WOI

**Nanopac Innovation Limited****ARBN 169 020 580****STOCK EXCHANGE INFORMATION****TOP 20 ORDINARY SHAREHOLDERS AS AT 27 March 2017**

Shareholder	Shares	% of issued
DATO DR CHENG KOK LEONG	22,221,172	37.780%
J P MORGAN NOMINEES AUSTRALIA	6,489,140	11.033%
NANOPAC CO LTD	6,000,000	10.201%
MRS CHOY MAY CHAN	2,589,842	4.403%
CHENG KOK LEONG	1,737,007	2.953%
LEE TAI KYU	1,500,000	2.550%
OOI CHOO HUAT	1,200,174	2.041%
MS WAI YEE CHIN	1,000,000	1.700%
CHONG AI LEE	644,887	1.096%
GOH POI LENG	467,690	0.795%
CHENG KOK KEONG	460,538	0.783%
HO NYUK LAM	330,809	0.562%
LAI YIN TING	300,000	0.510%
YONG VOON KIEN	300,000	0.510%
LAI KOK VOON	200,000	0.340%
CHIA CHUI HOONG	200,000	0.340%
POH GEOK SOO	197,998	0.337%
CHNG SEK KIAM	189,490	0.322%
LIM CHENG KEAT	182,469	0.310%
CHANG CHU KIAN	170,401	0.290%



---

**Analysis of Holdings as at 21-03-2017****Security Classes****CHESS Depositary Interests over Fully Paid Ordinary Shares**

<b>Holdings Ranges</b>	<b>Holders</b>	<b>Total Units</b>	<b>%</b>
<b>1-1,000</b>	0	0	0.000
<b>1,001-5,000</b>	0	0	0.000
<b>5,001-10,000</b>	0	0	0.000
<b>10,001-100,000</b>	0	0	0.000
<b>100,001-99,999,999,999</b>	20	46,381,617	78.858
<b>Totals</b>	<b>20</b>	<b>33,913,500</b>	<b>78,858</b>

**Substantial shareholders****Shares % of Issued**

<b>DATO DR CHENG KOK LEONG</b>	<b>22,221,172</b>	<b>37.780%</b>
<b>J P MORGAN NOMINEES AUSTRALIA</b>	<b>6,489,140</b>	<b>11.033%</b>
<b>NANOPAC CO LTD</b>	<b>6,000,000</b>	<b>10.201%</b>

**Nanopac Innovation Limited**

**ARBN 169 020 580**

---

**CORPORATE DIRECTORY**

**DIRECTORS**

Dr Cheng Kok Leong

CHIN WOI HO

**SECRETARY**

Andrew Bristow - Australia

Westco Secretaries Ltd - Samoa

**REGISTERED OFFICE – SAMOA**

c/- ASIACITI TRUST SAMOA LTD

2<sup>nd</sup> Floor, Building B

SNPF Plaza

Saulino

APIA SAMOA

**REGISTERED OFFICE – AUSTRALIA**

C/- HIGHGATE CORPORATE ADVISORS PTY LTD

Suite 214, Level 2, 33 Lexington Drive

BELLA VISTA NSW 2153

+61 2 9629 6188

**NOMINATED ADVISOR**

HIGHGATE CORPORATE ADVISORS PTY LTD

Suite 214, Level 2, 33 Lexington Drive

BELLA VISTA NSW 2153

+61 2 9629 6188

AUDITOR

CK & ASSOCIATES

CHARTERED ACCOUNTANTS

UNIT A-6-2, WISMA YOON CHENG

NO 726, JALAN IPOH

51200 KUALA LUMPUR

MALAYSIA

(MEMBER FIRM OF MALAYSIAN INSTITUTE OF ACCOUNTANTS)

CDI/SHARE REGISTRY

BOARDROOM PTY LIMITED

Level 12, 225 George Street

SYDNEY NSW 2000